[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-transthyretin-mediated-hattr-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-transthyretin-mediated-hattr-amyloidosis":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":24,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100442360",false,"NCT05040373","Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","Patisiran-LNP Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy\n\nExclusion Criteria:\n\n* There are no exclusion criteria for participation in this program.","FEMALE",{"count":17,"type":18},10,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal\u002Fneonatal\u002Finfant outcomes in women exposed to patisiran-LNP.",[22,23],"Hereditary Transthyretin-mediated (hATTR) Amyloidosis","Polyneuropathy",[25,26,27,28,29],"Hereditary neuropathic amyloidosis","Familial amyloidosis","Amyloidosis","Amyloidosis senile","Cardiac amyloidosis","RECRUITING","2026-05-28",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":34},"2020-08-01",{"date":38,"type":18},"2030-10-12",{"name":40,"class":41},"Alnylam Pharmaceuticals","INDUSTRY",7,""]